Pharmacokinetic properties of the novel synthetic cannabinoid 5f-apinac and its influence on metabolites associated with neurotransmission in rabbit plasma

The strong psychoactive effects of synthetic cannabinoids raise the need for the deeper studying of their neurometabolic effects. The pharmacokinetic properties of 5F-APINAC and its influence on metabolomics profiles associated with neurotransmission were investigated in rabbit plasma. Twelve rabbits divided into three groups received 1-mL 5F-APINAC at 0.1, 1 and 2 mg/kg. The intervention groups were compared with the controls. Sampling was performed at nine time points (0–24 h). Ultra-high-performance liquid chromatography–tandem mass spectrometry was used. The pharmacokinetics were dose-dependent (higher curve at a higher dose) with a rapid biotransforma-tion, followed by gradual elimination within 24 h. The tryptophan concentrations abruptly decreased (p < 0.05) in all tested groups, returning to the basal levels after 6 h. 5-hydroxylindole acetic acid increased (p < 0.05) in the controls, but this trend was absent in the treated groups. The aspartic acid concentrations were elevated (p < 0.001) in the treated groups. L-kynurenine was elevated (p < 0.01) in the intervention groups receiving 1 mg/kg to 2 mg/kg. Dose-dependent elevations (p < 0.01) were found for kynurenic acid, xanthurenic acid and quinolinic acid (p < 0.01), whereas the anthranilic acid trends were decreased (p < 0.01). The indole-3-propionic acid and indole-3-carboxaldehyde trends were elevated (p < 0.05), whereas the indole-3-lactic acid trajectories were decreased (p < 0.01) in the intervention groups. 5F-APINAC administration had a rapid biotransformation and gradual elimination. The metabolites related to the kynurenine and serotonergic system/serotonin pathways, aspartic acid innervation system and microbial tryptophan catabolism were altered. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Авторы
Shestakova K.M.1, 2 , Mesonzhnik N.V.1, 3 , Markin P.A.1, 2, 4 , Moskaleva N.E.1, 3, 4 , Nedorubov A.A.5 , Brito A.1 , Appolonova E.G.6 , Kuznetsov R.M.1 , Bochkareva N.L.1 , Kukharenko A.1 , Lyundup A.V. 7 , Tagliaro F.1, 2 , Appolonova S.A.1, 4
Журнал
Издательство
MDPI AG
Номер выпуска
7
Язык
Английский
Статус
Опубликовано
Номер
668
Том
14
Год
2021
Организации
  • 1 Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, Moscow, 119991, Russian Federation
  • 2 University of Verona, Verona, 37129, Italy
  • 3 World-Class Research Center “Digital Biodesign and Personalized Healthcare”, I.M. Sechenov First Moscow State Medical University, Moscow, 119991, Russian Federation
  • 4 Russian Center of Forensic-Medical Expertise of the Ministry of Health, Moscow, 125284, Russian Federation
  • 5 Center for Preclinical Research, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, Moscow, 119991, Russian Federation
  • 6 A. Butlerov Institute of Chemistry, Kazan Federal University, Kazan, 420008, Russian Federation
  • 7 Research and Educational Resource Center for Cellular Technologies of Peoples’ Friendship University of Russia, Moscow, 117198, Russian Federation
  • 8 Unit of Forensic Medicine, Department of Diagnostics and Public Health, University of Verona, Verona, 37129, Italy
Ключевые слова
5F-APINAC; Metabolites; Metabolomics; Neurotransmit-ters; Pharmacokinetics; Synthetic cannabinoids; UPLC-MS/MS
Дата создания
16.12.2021
Дата изменения
16.12.2021
Постоянная ссылка
https://repository.rudn.ru/ru/records/article/record/76758/
Поделиться

Другие записи